HC Wainwright Has Strong Forecast for AMLX FY2028 Earnings

Key Points

• HC Wainwright raised Amylyx’s FY2028 EPS forecast to a loss of $0.97 per share from a prior loss estimate of $1.08, while maintaining a Buy rating and $55 price target. The firm projects positive EPS of $3.22 in FY2029 and $6.40 in FY2030.
• Amylyx recently reported a quarterly loss of $0.39 per share, missing the $0.36 consensus estimate. Despite the miss, analyst sentiment remains broadly positive, with an average Buy rating and $36.25 consensus price target.
• Avexitide trial success has strengthened the company’s outlook after Amylyx said its Phase 3 LUCIDITY study reduced hypoglycemic events by 55%, potentially supporting an FDA filing by the end of 2026. The company is also raising about $500 million through a stock offering, which bolsters its balance sheet but creates dilution risk.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Investment analysts at HC Wainwright boosted their FY2028 EPS estimates for shares of Amylyx Pharmaceuticals in a research note issued to investors on Tuesday, August 18th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.97) per share for the year, up from their previous estimate of ($1.08). HC Wainwright has a "Buy" rating and a $55.00 price target on the stock. The consensus estimate for Amylyx Pharmaceuticals' current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals' FY2029 earnings at $3.22 EPS and FY2030 earnings at $6.40 EPS.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03).

AMLX has been the topic of a number of other research reports. Guggenheim lifted their target price on shares of Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the company a "buy" rating in a research note on Wednesday. Wolfe Research upgraded Amylyx Pharmaceuticals to a "strong-buy" rating in a research note on Monday. Weiss Ratings reissued a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Citigroup boosted their price objective on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Finally, Robert W. Baird increased their target price on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an "outperform" rating in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Amylyx Pharmaceuticals has an average rating of "Buy" and an average target price of $36.25.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ AMLX opened at $38.60 on Thursday. The stock has a market cap of $4.30 billion, a PE ratio of -26.99 and a beta of -0.21. Amylyx Pharmaceuticals has a 1 year low of $7.82 and a 1 year high of $39.07. The firm has a fifty day moving average price of $19.38 and a 200-day moving average price of $16.35.

Insider Activity

In other news, insider Gina Mazzariello sold 15,000 shares of the company's stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $274,800.00. Following the sale, the insider directly owned 194,090 shares in the company, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.90% of the company's stock.

Institutional Trading of Amylyx Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its stake in shares of Amylyx Pharmaceuticals by 17.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 903,192 shares of the company's stock worth $12,544,000 after purchasing an additional 131,944 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter valued at approximately $705,000. Bank of New York Mellon Corp lifted its holdings in shares of Amylyx Pharmaceuticals by 15.5% in the 1st quarter. Bank of New York Mellon Corp now owns 251,104 shares of the company's stock worth $3,490,000 after buying an additional 33,757 shares during the period. Vanguard Group Inc. grew its holdings in Amylyx Pharmaceuticals by 10.1% during the 4th quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company's stock worth $70,123,000 after acquiring an additional 531,162 shares in the last quarter. Finally, Stempoint Capital LP boosted its stake in shares of Amylyx Pharmaceuticals by 18.5% during the first quarter. Stempoint Capital LP now owns 669,685 shares of the company's stock valued at $9,309,000 after purchasing an additional 104,545 shares in the last quarter. Hedge funds and other institutional investors own 95.84% of the company's stock.

Key Headlines Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Phase 3 LUCIDITY success supports avexitide approval prospects. Amylyx reported that avexitide met the primary and secondary endpoints in the LUCIDITY trial for post-bariatric hypoglycemia, reducing hypoglycemic events by 55%. The results could support an FDA filing by the end of 2026 and advance the company’s first potential commercial product. Reuters article
• Positive Sentiment: Analysts raised price targets and ratings. Guggenheim increased its target to $55 from $40 with a Buy rating, while Robert W. Baird raised its target to $52 from $28 with an Outperform rating. Wolfe Research also upgraded the stock to Strong Buy. HC Wainwright retained a Buy rating and a $55 target. Benzinga analyst coverage
• Positive Sentiment: Long-term earnings estimates improved significantly. HC Wainwright raised its FY2029 EPS forecast to $3.22 from $1.66 and its FY2030 estimate to $6.40 from $3.74. The revisions suggest analysts see greater commercial potential for avexitide and a faster path to profitability.
• Neutral Sentiment: Shares are trading near the top of their 52-week range. The new high reflects strong investor momentum following the trial announcement, although the stock’s valuation and future performance now depend heavily on regulatory progress, commercialization, and execution.
• Negative Sentiment: Amylyx is raising substantial capital, creating dilution risk. The company priced an upsized underwritten offering of 14.09 million shares at $35.50 each, expected to raise approximately $500 million before expenses. Underwriters may purchase an additional 2.11 million shares, which could dilute existing shareholders even as the proceeds strengthen Amylyx’s balance sheet. Amylyx public offering announcement

Amylyx Pharmaceuticals Company Profile

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source